sábado, 21 de noviembre de 2026
Is MAHA’s think tank in the tank? Tax filings show low reserves Known for D.C. roundtables, MAHA Institute was down to $171,000 in December (++)
https://www.statnews.com/2026/11/20/maha-institute-tax-filings-rfk-jr-health-agenda-spending/
By Isabella CuetoNov. 20, 2026
Chronic Disease Reporter
Medicare pilot will test ‘food is medicine’ and other lifestyle programs to counter chronic diseases
Kennedy says 15 groups will get a chance to prove preventive programs are worth coverage
https://www.statnews.com/2026/11/20/kennedy-food-is-medicine-maha-elevate-pilot/
By Isabella CuetoNov. 20, 2026
Chronic Disease Reporter
When should medical school start? Keep those letters coming!
https://www.statnews.com/2026/11/21/stat-letters-to-editor-medical-school-pediatric-emergency-care/
By Torie BoschNov. 21, 2026
Editor, First Opinion
Patients have little say in how brain implant trials are done. Ian Burkhart wants to change that New recommendations from a patient coalition urge device developers to do better
https://www.statnews.com/2026/11/20/ian-burkhart-how-brain-implant-trials-can-serve-patients-better/
By O. Rose BroderickNov. 20, 2026
Disability in Health Care Reporting Fellow
ICE detention of Princeton scientist rattles academia Case of Chinese graduate student seems to crystallize fears among non-U.S. researchers
https://www.statnews.com/2026/11/20/princeton-researcher-eva-yi-xie-ice-detention-rattles-interational-scholars/
By Anil OzaNov. 20, 2026
General Assignment Reporter
Peptide market poised to explode with new Hims and Noom launches Despite lack of safety data, an HHS decision allows experimental compounds to go mainstream
https://www.statnews.com/2026/11/19/hims-noom-enter-peptide-market-mainstream-products-health-risks/
By Sarah Todd and Katie PalmerNov. 19, 2026
FDA rejects Capricor Therapeutics’ Duchenne therapy, a decision that was a long time coming A public pressure campaign couldn’t alter the hard reality: The drug didn’t work
https://www.statnews.com/2026/11/20/fda-rejects-capricor-duchenne-therapy/
By Adam FeuersteinNov. 20, 2026
Adam Feuerstein, a senior writer and biotech columnist, is the author of Adam’s Biotech Scorecard, a subscriber-only newsletter about the crossroads of drug development, business, Wall Street, and biotechnology.
How Kennedy and MAHA could help stop measles RFK Jr. could reach the vaccine-hesitant during the runaway outbreak
https://www.statnews.com/2026/11/21/rfk-jr-maha-measles-outbreak-elimination-status-promote-mmr-vaccine/
By Brinda AdhikariNov. 21, 2026
Adhikari is a journalist and co-host of the “Why Should I Trust You?” podcast.
Suscribirse a:
Entradas (Atom)

